|
Production of 177Lu and formulation of Ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone-seeking radiopharmaceutical
|
F. Johari Daha   , S. Shafiei , Sh. Sheibani , Y.H. Tavakoli , M. Mazidi , M.H. Mirfalah , M.H. Babaei |
| , mbabaei@aeoi.org.ir |
|
|
Abstract: (15105 Views) |
| Background: Owing to its favourable decay
characteristics 177Lu [T1/2= 6.71 d, Eβ(max)= 497
keV] is an attractive radionuclide for various
therapeutic applications. Ethylene diamine tatramethylene
phosphonate (EDTMP) is one of the most
widely used ligands which form stable complexes with
various radionuclides and all the complexes.
Materials and Methods: Enriched 176Lu2O3 was
dissolved in 0.1 N HCl and evaporated several times
and 176LuCl3 target was irradiated at 2.6×1013 n.Cm-
2.S-1 thermal neutron flux for 14 days.177LuCl3 was
dissolved in 1N HCl. EDTMP was dissolved in double
distilled water at pH=7.5-8.5 and freeze-dried kits
was radiolabeled with 177LuCl3. Distribution studies
were done in healthy mice. Results: The yield of 177Lu
was (~220 TBq/g 6000 Ci/g), the radionuclidic purity
was ~99%.The radiolabeling yield of EDTMP kits at
37°C after 30 min and 4 hours was 98±0.5% and
after 72 hours was 90±2.1%, the in vitro stability in
human serum at 37°C up to 72 hours post radiolabeling
was 85±1.8%.The biodistribution studies of
177Lu-EDTMP and 177LuCl3 in normal mice showed
skeleton uptake and low soft-tissue concentration.
Conclusion: In this study, we produce ~220 TBq/g
(6000 Ci/g) of 177Lu by neutron activation of 176Lu in
the Tehran Research Reactor. Our results showed
177Lu-EDTMP as a bone-seeking radiopharmaceutical.
Due to its suitable nuclear characteristics 177Lu
appears to be worthwhile for palliative therapy of
bone metastasis. Iran. J. Radiat. Res., 2010 7 (4): 229-234 |
|
| Keywords: DTMP, Bone-seeking radiopharmaceuticals, 177Lu. |
|
|
Full-Text [PDF 252 kb]
(4243 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
